Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (April 8th Preview)
-
Corporate M&A reshapes Gilead’s oncology engine with next-gen ADC platform
Gilead Sciences agreed to acquire German ADC specialist Tubulis for $3.15 billion upfront, with up to $1.85 billion in milestones, expanding the company’s antibody-drug conjugate pipeline beyond Trodelvy. The deal also brings Tubulis’ conjugation, linker, and payload technologies, positioned to improve selectivity and reduce off-target toxicity. Tubulis’ lead candidate, TUB-040, is a NaPi2b-directed topoisomerase-I inhibitor ADC in the Phase Ib/II NAPISTAR1-01 study (NCT06303505) for platinum-resistant ovarian cancer and non-small cell lung cancer. Tubulis also has TUB-030, a 5T4-targeting ADC in clinical development across solid tumors, with prior fast track designation for TUB-040. Following multiple acquisitions in early 2026, Gilead is signaling a shift from rapid dealmaking to integration while leaning into ADC technology depth. If TUB-040’s emerging clinical activity translates into durability, analysts expect Gilead to build a broader oncology stack with additional targets and mechanisms. The transaction is expected to close in the second quarter of 2026, with Tubulis’ Munich site set to operate as a dedicated ADC research organization within Gilead.
-
Neurocrine locks in Prader-Willi hyperphagia franchise via Soleno acquisition
Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, aiming to broaden its marketed endocrinology and rare-disease portfolio. The acquisition includes Vykat XR (diazoxide choline), the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome (PWS). Vykat XR received FDA approval in March 2025 and generated $190 million in revenue in its first year, including $92 million in Q4 2025. Soleno also reported profitability after the product ramp, supporting the rationale for Neurocrine’s portfolio diversification. For Soleno, the transaction follows a clinical and commercial focus on a patient population of about 10,000 people in the U.S., with the core PWS pathology driven by abnormalities on chromosome 15. Neurocrine leadership highlighted plans to expand Vykat XR’s reach by leveraging existing endocrinology and rare disease launch experience. The deal is expected to close within 90 days, subject to regulatory approvals and customary conditions.
-
Regulatory and policy push: FDA proposes faster early trials and “domestic-first” incentives
The FDA is using its proposed 2027 budget to lay out policy ideas intended to speed early clinical development in the U.S. and encourage domestic drug manufacturing. FDA Commissioner Marty Makary said the agency needs “giant, big ideas” to counter China’s lead in early-stage clinical execution. Among the proposals: changes aimed at making it easier to initiate first-in-human trials in the U.S., and advantages for U.S.-based generics manufacturers. The initiatives come amid broader political and trade pressure on biopharma supply chains, with domestic production commitments increasingly tied to tariff risk. The budget framework is also being positioned as part of a shift from reactive to proactive regulation, with the agency seeking more predictability for sponsors launching new products. Public discussion around these proposals centers on timeline reductions and whether the reforms can be implemented fast enough for ongoing pipeline programs. For biotech operators, the immediate takeaway is that regulatory strategy is being explicitly linked to industrial policy, not only science review.
-
Diagnostics access expands: at-home HPV self-collection gets FDA 510(k) clearance
Waters received FDA 510(k) clearance for its BD Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, enabling an at-home workflow for high-risk HPV screening. The test is designed to improve access to cervical cancer prevention by allowing patients to self-collect samples and mail them for laboratory processing. Waters evaluated accuracy with the National Cancer Institute’s Cervical Cancer “Last Mile” Initiative SHIP Trial, reflecting an effort to validate self-collection outside traditional clinic settings. The assay detects high-risk, carcinogenic HPV genotypes and is processed on BD COR Systems. Waters acquired the test through its $18.8 billion purchase of Becton Dickinson’s Biosciences & Diagnostic Solutions business. Waters says the test will be available by prescription in the near future and that coverage includes Medicare, Medicaid, and private insurers. The FDA clearance strengthens the patient-access case for mailing-based screening programs, which have been repeatedly targeted to close screening gaps.
-
AI-enabled immunology readouts: new single-cell method tracks RNA and protein together
Researchers reported CIPHER-seq, a single-cell platform designed to measure RNA and proteins simultaneously in the same immune cell, aimed at closing the gap between cytokine gene expression and functional protein output. The method captures multiple molecular layers in real time, including surface and intracellular proteins, cytokines not yet released, and genome-wide RNA. The work appears in Scientific Reports and was developed by teams at the Sylvester Comprehensive Cancer Center at the University of Miami, with collaborators at UCSF and the Helen Diller Family Comprehensive Cancer Center. The platform was validated by stimulating peripheral blood mononuclear cells and tracking immune activation. Co-senior authors say RNA often doesn’t translate cleanly into protein levels for cytokines, which can complicate interpretation in RNA-only studies. In CIPHER-seq, researchers also reported metabolic remodeling during activation alongside cytokine induction. The platform is expected to support more precise immune-state profiling for translational immunotherapy efforts and patient stratification.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.